Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology

Tanashyan, M. M.; Кузнецова, П.И.; Raskurazhev, A. A.

doi:10.17116/jnevro2020120041123

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are differences between laboratory and clinical resistance. Laboratory resistance refers to the lack of residual platelet reactivity (RPR) blocking effect.Clinical resistance suggests the development of atherothrombotic events on the background of the ASA use [20,21,22].…”

Section: R E S U L T S a N D Discussionmentioning

confidence: 99%

“…Possible causes of aspirin resistance associated with insufficient compliance to therapy, low bioavailability of drugs, inadequately prescribed dose, poor intestinal absorption, clinically significant interactions with other drugs, functional immaturity of platelets, smoking, hypercholesterolemia, hyperglycemia, obesity, stress, comorbid pathology, high levels of pro-inflammatory cytokines, which are an additional source of thromboxane TXA2 and other fac-tors have been widely discussed in the publications [14,20,21,22,24,49].…”

Section: Modifiable Factors Affecting Antiplatelet Therapy Responsive...mentioning

confidence: 99%

See 1 more Smart Citation

Factors influencing the effectiveness of antiplatelet therapy

Кантемирова¹,

Жидовинов²,

Абдуллаев³

et al. 2022

ArveMED

View full text Add to dashboard Cite

In recent years, significant advances in the diagnosis and treatment of cardiovascular diseases have been achieved in the healthcare of most countries. However, among the causes of mortality in patients with coronary heart disease, arterial thrombosis takes one of the leading positions. Antiplatelet drugs are prescribed to prevent thrombotic complications, which can be used as mono- or two-component therapy. In case of atherosclerosis in arteries, acetyl-salicylic acid (ASA) or clopidogrel can be used as monotherapy; treatment of acute coronary syndrome (ACS) and percutaneous coronary interventions (PCI) required using of double antiplatelet therapy (DAT), including acetylsalicylic acid drugs together with one antiplatelet agent from the group of thienopyridine derivatives — blockers of P2Y12 platelet receptors (clopidogrel, ticagrelor, prasugrel). In patients with ACS who underwent primary PCI or thrombolysis followed by PCI, the duration of DAT is 12 months, and clopidogrel is the drug of choice [16, 30]. According to various literature sources about 20–40% of patients have low effectiveness of antiplatelet therapy, which can lead to thrombosis, stent thrombosis and thromboembolic complications. This review provides an analysis of modifiable and nonmodifiable factors contribution to the development of clinical and laboratory resistance of antiplatelet agents.

show abstract

Section: R E S U L T S a N D Discussionmentioning

confidence: 99%

Section: Modifiable Factors Affecting Antiplatelet Therapy Responsive...mentioning

confidence: 99%

Factors influencing the effectiveness of antiplatelet therapy

Кантемирова¹,

Жидовинов²,

Абдуллаев³

et al. 2022

ArveMED

View full text Add to dashboard Cite

show abstract

Issues of management of patients with post-stroke cognitive impairment

Локшина

Grishina

2023

RJTAO

View full text Add to dashboard Cite

Stroke is second to third most common cause of death in the population and the leading cause of disability. More than 12 million strokes are registered annually in the world. Cognitive impairments (CI) significantly contribute to the disability of patients after a stroke, which limit daily activities no less than movement disorders. The article presents data on the prevalence of post-stroke CI (PSCI), examines the issues of epidemiology, risk factors, the main clinical and pathogenetic data of disorders, the peculiarities of their diagnosis and treatment. The issues of the dipyridamole use for the prevention of stroke and in patients with PSCI are discussed.

show abstract

Concept of 5P-medicine for prevention of acute cerebral ischemia in women

Манышева

2022

Medicinskij alfavit

View full text Add to dashboard Cite

The objective. To evaluate the effectiveness of the 5P-model for the prevention of acute cerebral ischemia in Dagestan women.Materials and methods. The prospective study included 35 women permanently residing in Dagestan. The mean age was 66.46 ± 10.9 years. Each participant of the study was individually interviewed and examined clinically, neurologically, an additional examination included: complete blood test, biochemical blood test, coagulation test, molecular genetic study for 11 candidate gene mutations signiﬁcant for the occurrence of ischemic stroke, electrocardiography, neuroimaging.Results. By analyzing the results of the study, individual background conditions that predispose to the occurrence of ischemic stroke were established. The results of the examination were explained to each participant, there were given the recommendations on lifestyle modiﬁcation, a diet was prescribed and the necessary therapy was selected. In the process of dynamic observation for 4 years the observed group had no episodes of acute cerebrovascular accident.Conclusions. The study conﬁrms the effectiveness of the use of the 5P-model for the prevention of acute cerebral ischemia in women Dagestan and declare a positive experience of its application.

show abstract

Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology

Cited by 3 publications

References 16 publications

Factors influencing the effectiveness of antiplatelet therapy

Factors influencing the effectiveness of antiplatelet therapy

Issues of management of patients with post-stroke cognitive impairment

Concept of 5P-medicine for prevention of acute cerebral ischemia in women

Contact Info

Product

Resources

About